# Ikervis for DED Due to GVHD Post Allo-HSCT

> **NCT04636918** · PHASE4 · UNKNOWN · sponsor: **Singapore Eye Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Leukemia (Both ALL and AML)
- MDS-EB-1

## Interventions

- **DRUG:** Cyclosporine Ophthalmic

## Key facts

- **NCT ID:** NCT04636918
- **Lead sponsor:** Singapore Eye Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-28
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04636918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04636918, "Ikervis for DED Due to GVHD Post Allo-HSCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04636918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*